

Nelson B Watts

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7525434/nelson-b-watts-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

4,953
citations

19
h-index

30
g-index

30
ext. papers

5,771
ext. citations

9.8
avg, IF

4.95
L-index

#	Paper	IF	Citations
25	Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVEExtend phase 3 trial. <i>Osteoporosis International</i> , 2021 , 32, 55-61	5.3	1
24	Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. <i>Journal of Women's Health</i> , 2021 , 30, 1416-1430	3	2
23	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , 2020 , 26, 1-46	3.2	164
22	Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. <i>Obstetrics and Gynecology</i> , 2020 , 135, 1313-1326	4.9	13
21	Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. <i>New England Journal of Medicine</i> , 2020 , 382, 328-340	59.2	59
20	Letter to the Editor: "Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-Analysis". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	1
19	History of etidronate. <i>Bone</i> , 2020 , 134, 115222	4.7	12
18	Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population. <i>JBMR Plus</i> , 2020 , 4, e10401	3.9	3
17	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2443-2452	5.6	23
16	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019 , 30, 1187-1194	5.3	15
15	Postmenopausal Osteoporosis: A Clinical Review. <i>Journal of Women's Health</i> , 2018 , 27, 1093-1096	3	41
14	Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. <i>Obstetrics and Gynecology</i> , 2018 , 132, 147-160	4.9	59
13	Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. <i>Obstetrics and Gynecology</i> , 2018 , 132, 1252-1264	4.9	26
12	Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. <i>New England Journal of Medicine</i> , 2017 , 377, 28-40	59.2	214
11	Adverse bone effects of medications used to treat non-skeletal disorders. <i>Osteoporosis International</i> , 2017 , 28, 2741-2746	5.3	14
10	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 44-51	5.6	176
9	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 157-66	5.6	290

8	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016 , 22, 1111-8	3.2	115
7	2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 472-81	3.5	55
6	Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 645-53	6.3	110
5	Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 22-30	3.5	93
4	A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. <i>American Journal of Medicine</i> , 2000 , 109, 267-76	2.4	859
3	Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. <i>American Journal of Medicine</i> , 1997 , 103, 468-76	2.4	124
2	Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. <i>American Journal of Medicine</i> , 1993 , 95, 557-67	2.4	310
1	Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 1990 , 323, 73-9	59.2	847